Summary: Cytotoxic anticancer drugs are the most challenging therapeutic agents among all medicines with relatively narrow efficacy profiles. Therefore, medical oncologists have to practically manage the risk of severe toxic effects to optimize treatment outcomes. Dose and treatment-schedule recommendations for cytotoxic anticancer agents are determined on the basis of clinical trials. Patients enrolled in clinical trials are those likely to receive the drug in clinical practice, excluding those with conditions such as organ dysfunction, obesity, advanced age, or comorbidity. On the other hand, the 'real world' includes large numbers of such patients who do not meet the eligibility criteria of clinical trials. However, there is a paucity of data from sufficiently powered pharmacokinetic and pharmacodynamic studies to support dosage recommendations in such patients. Consequently, dose levels and treatment schedules for chemotherapy in these subjects are somewhat arbitrary and not evidence-based. Pharmacokinetic and pharmacodynamic studies of patients in the 'real world' are needed to address this issue. In this review article, we describe general aspects of clinical pharmacology in cancer patients enrolled in clinical trials and those in the 'real world,' and introduce recent findings regarding the pharmacokinetic and pharmacodynamic properties of irinotecan and S-1 in 'real world' cancer patients.
Introduction
Dating back to the initial use of nitrogen mustards for the treatment of malignant lymphoma, 1) numerous chemotherapeutic agents have been developed and used clinically to manage a variety of tumors. Cytotoxic anticancer drugs include alkylating agents, platinum analogues, antimetabolites, topoisomerase-interacting agents, and antimicrotubule agents. Although some chemotherapeutic agents are associated with organ-specific toxicity, most are myelosuppressive and exhibit dose-dependent cytotoxicity against a range of proliferating cells, including normal cellular elements of bone marrow, gastrointestinal mucosa, and hair follicles, in addition to proliferating tumor cells. 2) Because the pharmacologic treatment of human malignancies involves the clinical use of some of the most challenging therapeutic agents, medical oncologists must practically manage the risk of severe adverse drug reactions, potentially leading to treatment-related death, and optimally use cytotoxic drugs with relatively narrow efficacy profiles. Dose and treatment-schedule recommendations for cytotoxic anticancer agents are based on the results of phase 1, 2, and 3 clinical trials. Patients enrolled in clinical trials are typically those likely to receive the drug in clinical practice, but exclude those with conditions such as poor performance status, organ dysfunction, obesity, advanced age, or comorbidity. Consequently, such cancer patients often poorly are represented. On the other hand, the 'real world' includes large numbers of such patients who do not meet the eligibility criteria of clinical trials. Unfortunately, there is a paucity of information from sufficiently powered studies evaluating the effects of such conditions on pharmacokinetics and pharmacodynamics (efficacy and toxicity). Accordingly, dose levels and treatment schedules for chemotherapy in these subjects are somewhat arbitrary and not evidence-based. Clinical pharmacology studies of patients in the 'real world,' including analyses of pharmacokinetics, pharmacodynamics and pharmacogenomics, are needed to address these issues. A substantial number of such clinical pharmacological studies have recently been performed in Western countries. The results have been summarized in review articles, [3] [4] [5] [6] [7] [8] [9] including publications by scientific societies such as the American Society of Clinical Oncology 6) and the International Society of Geriatric Oncology. 7, 9) The general consensus is that further studies of pharmacokinetics and other factors are required to confirm currently available results and to establish more robust evidence to support dosage recommendations. As compared with Western countries, however, only a small number of such studies have been performed in Japan.
In this review article, we describe the general features of clinical pharmacological studies performed in cancer patients enrolled in clinical trials and those in the 'real world.' Next, we introduce recent findings regarding the pharmacokinetics and pharmacodynamics of irinotecan and S-1 in 'real world' patients with cancer, especially focusing on the pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) in patients with severe renal failure who received irinotecan and the pharmacokinetics of 5-fluorouracil (5-FU) in patients with a large body surface area (BSA) or advanced age who received S-1.
Defining Optimal Dose Levels and Treatment Schedules for Chemotherapeutic Agents
During the development of cytotoxic anticancer drugs, phase 1 trials represent the first use of investigational agents in humans. Major objectives of phase 1 trials are to characterize the agent's pharmacokinetic and toxicological properties and to determine appropriate dose levels and treatment schedules for phase 2 trials. In the general design for phase 1 studies, successive cohorts of 3 to 6 patients are assigned to receive increasing doses of an experimental therapy, with the goal of determining dose-limiting toxicity (DLT) and the maximum-tolerated dose (MTD). The recommended dose for subsequent phase 2 trials is based on DLT and the MTD. 10, 11) In phase 1 trials in oncology, patients who have advanced cancer and in whom standard treatment options have been exhausted are typically enrolled. Potential therapeutic benefits of developing a new drug are also tested in phase 1 studies, usually as a secondary endpoint. Evaluation of therapeutic benefits in phase 1 is warranted from a developmental standpoint, given the positive correlation between response rate in phase 1 and Food and Drug Administration approval. 10, 11) The primary endpoint of phase 2 trials is to evaluate the efficacy of the developmental drug against various histologic types or molecular subtypes of cancer. 10) If successful, phase 2 trials provide the first evidence of efficacy of the drug in humans. Phase 2 studies are larger than phase 1 trials in terms of the number of patients enrolled (³70 patients) and use potentially therapeutic dose levels and schedules; in general, the subjects are not heavily pretreated. Classic phase 2 trials are single-arm, open-label interventional studies. Investigators compare the results with historical controls to make a 'go/no go' decision as to whether the new anticancer agent should proceed to randomized phase 3 studies.
Phase 3 trials are large, randomized, multi-institutional, and resource-intensive studies that seek to determine whether the investigational new treatment demonstrates statistically and clinically important benefits over a previously accepted standard of care. 10, 11) The hallmarks of phase 3 trials include a control group given standard chemotherapy, a selection of patients that is broad enough for the results to be applied in a community, and the measurement of endpoints that have direct relevance to patients, such as survival or symptomatic relief. 12) Phase 3 oncology trials are the most expensive and time-consuming component of the drug development process. The average number of patients enrolled in each phase 3 trial is approximately 500, and completion typically requires 3 to 5 years. 13) However, the results of phase 3 trials continue to have the greatest impact on treatment decisions by oncologists and remain pivotal to the approval of a new drug by regulatory agencies.
Pharmacokinetics and Pharmacodynamics of Cytotoxic Anticancer Drugs
Because the dose of cytotoxic anticancer agents is based on the MTD, the therapeutic window of these agents is narrow. 14) Excessive toxicity is thus common, although death from chemotherapy-related toxicity is rare. Clinical pharmacology has had a strong impact on the field of oncology, because it attempts to scientifically explain and predict causes for variability in drug response. Pharmacokinetic studies play important roles not only in the preclinical and clinical development of new anticancer agents, but also in clinical practice, where the results of such studies are used to maximize therapeutic benefit and minimize toxicity. Pharmacokinetics has been used (1) to assess whether a given dose regimen of chemotherapy provides a potentially effective pattern of systemic exposure to the drug, (2) to monitor the magnitude of intrapatient and interpatient variability, (3) to assess whether changes in drug disposition or metabolism are related to the development of toxicity or the lack of efficacy, and (4) to predict or monitor drug-drug interactions, with the ultimate goal of improving treatment response and minimizing toxicity by dose individualization.
Relations between pharmacokinetics and severe anticancer druginduced toxicities, especially hematological toxicities, have been well established for many anticancer agents, including etoposide, irinotecan, paclitaxel, docetaxel, and pemetrexide. [15] [16] [17] [18] [19] [20] Relations between the area under the concentration-time curve (AUC) and decreased neutrophil counts have been represented with Emax models. On the other hand, pharmacokinetic associations accounting for the therapeutic efficacy of a chemotherapeutic agent have been more difficult to establish because of the multiplicity of factors affecting tumor response, as well as the time lapse from the start of treatment to initial evidence of a therapeutic response. To date, relations between systemic exposure to 5-FU and tumor response or survival have been demonstrated. 21, 22) From Patients in Clinical Trials to Those in the 'Real World' Dosing recommendations in oncology are usually based on the results of clinical trials including patients considered to be representative of those most likely to be given the study drug in clinical practice. Therefore, there are eligibility requirements that strictly define and limit patients enrolled in clinical trials. Typically, investigators only enroll cancer patients who have good performance status, good functions of organs such as the liver and kidney (organs involved in drug metabolism, elimination, or both), good bone-marrow function (related to hematological toxicity), an age of 70 (or 75) years or younger, and no obesity, comorbidity, or polypharmacy. Consequently, the recommended dose based on the results of clinical trials is not necessarily suitable for patients who do not satisfy these eligibility criteria.
In the 'real world,' there are a considerable number of cancer patients who do not meet the eligibility criteria of oncology clinical trials (unfit patient population). The unfit population includes patients who have poor performance status, organ dysfunction, advanced age, obesity, comorbidity, or polypharmacy. The unfit population even includes patients who have unidentified polymorphisms in genes related to the pharmacokinetics or pharmacodynamics of a given anticancer drug during clinical trials (Fig. 1) . These are not independent factors. For example, many elderly and obese patients have organ dysfunctions and comorbidities and receive polypharmacy. It is therefore important to perform clinical pharmacological studies in 'real world' unfit cancer patients to analyze pharmacokinetics, pharmacodynamics (efficacy and toxicity), and pharmacogenomics and thereby establish evidencebased chemotherapy in such patients. Another approach would be to conduct clinical trials in unfit populations to delineate appropriate doses and treatment-schedule for such patients.
Organ dysfunction: Physiologic conditions that influence liver and renal function can have dramatic effects on the pharmacokinetics of a drug in patients. Since the early 1980s, the effects of renal and hepatic dysfunction on the pharmacokinetics of anticancer drugs have been evaluated. 23) Renal function is relatively easily to monitor by the glomerular filtration rate, derived by directly measuring the creatinine clearance (CL cr ) on the basis of 24-h creatinine excretion into urine or by calculation from the serum creatinine concentration (or by both). 24, 25) However, it should be noted that a portion of creatinine is subjected to tubular secretion via organic cation transporter 2. 26) Since inulin is filtrated freely at the glomerulus and is neither reabsorbed nor secreted via tubules after glomerular filtration, its rate of excretion is identical to the glomerular filtration rate.
27) Renal-function-dependent alterations in tubular excretion and re-absorption are relatively difficult to estimate owing to the involvement of a variety of transporters. 28) Generally, hepatic function is more difficult to quantify than renal function. Hepatic dysfunction is mainly associated with abnormal biologic liver test results reflecting chronic cholestasis with elevated levels of bilirubin, alkaline phosphatase, and £-glutamyl transferase, with or without abnormal levels of aspartate aminotransferase, alanine aminotransferase, or both. 29) Pharmacokinetics, efficacy, tolerance, and dosage adjustment of cytotoxic anticancer drugs in Western cancer patients receiving hemodialysis have been summarized by Janus et al.
4)
Elderly patients: The elderly population has increased in recent years owing to the prolongation of the average life expectancy, and the incidence of cancer is rising among the elderly. Consequently, the number of elderly patients with cancer is increasing. Although most cancers occur in elderly individuals, elderly patients have been underrepresented in clinical trials of cancer chemotherapy, 20) leading to inadequate data to support evidence-based decisions with regard to chemotherapy. 7) Older cancer patients display considerable heterogeneity in their handling of drugs as a result of age-related changes in body composition, including decreased muscle mass, increased adipose tissue, and decreased liver and renal functions. Aging is accompanied by a ³30% decrease in liver volume and a ³40% decrease in hepatic blood flow. 30) Thus, the clearance of drugs with a high hepatic elimination rate, which is limited by blood flow, might be decreased in the elderly. 31, 32) Age-related decreases in the functions of some drug-metabolizing enzymes have been identified, but their clinical significance remains uncertain. 30, 33) The pharmacokinetic behavior of most anticancer drugs has thus not yet been adequately characterized in elderly patients. 34, 35) Hurria and Lichtman 8) reported that data on age-related changes in chemotherapy pharmacokinetics are inconsistent. Although a few studies have reported age-related differences in chemotherapy pharmacokinetics, most have found no significant difference or only subtle differences in pharmacokinetics with aging. On the other hand, age-related differences in pharmacodynamics (toxicity) have commonly been noted. The International Society of Geriatric Oncology Taskforce recommended that clinical trials should incorporate an analysis of the pharmacokinetic and pharmacodynamic effects of aging in patients who receive chemotherapy. The Taskforce also recommended that currently available data be reanalyzed according to age to improve the management of cancer in older patients.
7)
Obese patients: The World Health Organization has reported that worldwide obesity has nearly doubled since 1980 and now represents the fifth leading risk factor for global mortality, responsible for the deaths of at least 2.8 million adults each year (http:// www.who.int/mediacentre/factsheets/fs311/en/). The proportion of the population that is overweight is projected to increase over the coming years in many industrialized nations, making this a major public health concern. 36) Considerable evidence suggests that the dose intensity of chemotherapy received by overweight and obese patients with cancer in actual clinical practice is often lower than the recommended dose intensity 5) ; nevertheless retrospective and prospective clinical data have shown an association between dose intensity and both clinical efficacy and toxicity. In response to increasing rates of obesity, and variability and uncertainty about the appropriate dose regimens of chemotherapy in obese patients, the American Society of Clinical Oncology has issued clinical practice guidelines for appropriate chemotherapy dosing for obese adult patients with cancer. 6) In the absence of evidence suggesting increased treatment-related toxicity among obese patients who receive chemotherapy, the guidelines recommend that, after considering any comorbidities, chemotherapy dosing should be calculated on the basis of BSA using actual weight, rather than an estimate or idealization of weight.
6) Lyman and Sparreboom 5) concluded that pharmacokinetic studies performed to date support the use of actual body weight to calculate the doses of most chemotherapeutic agents in obese patients; however, further research is needed. 
Irinotecan
Irinotecan is a camptothecin analogue with potent antitumor activity resulting from inhibition of topoisomerase I. This anticancer drug is now widely used to treat colorectal, lung, and other types of cancer. 37, 38) DLT of irinotecan includes severe leukopenia, neutropenia, and diarrhea. 39) General pharmacokinetics: Irinotecan is unique among camptothecin analogs in that it must first be converted by a carboxylesterase (CES)-converting enzyme to the active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) (Fig. 2) .
40,41) SN-38 is the major metabolite believed to be responsible for irinotecan's biologic effects, including efficacy and toxicity. It is subsequently detoxified, predominantly by UDP-glucuronosyltransferase (UGT) 1A1 in the liver, to form SN-38 glucuronide. Transporters expressed in the liver are implicated in various aspects of SN-38 pharmacokinetics. A primary active transport system is involved in permeation of SN-38 across canalicular membranes in both humans and rats, and ATP-binding cassette transporter, subfamily C, member 2 (ABCC2) and ATP-binding cassette transporter, subfamily G, member 2 (ABCG2) mediate its biliary excretion. [42] [43] [44] A portion of SN-38 produced in the liver is thought to be transported to the systemic circulation across sinusoidal membranes by unidentified transporter(s) because SN-38 is detectable in plasma immediately after irinotecan injection in patients with cancer. SN-38 is a substrate of the organic anion transporting polypeptides (OATPs) 1B1 and 1B3, which are localized on sinusoidal membranes in humans 45, 46) and participate in the uptake of SN-38 by hepatocytes.
47) The contribution of OATP1B1 to the hepatic uptake of SN-38 was the highest, followed by that of OATP1B3. 47) Interindividual variability in clearance of irinotecan is reported to be approximately 30%, whereas that of SN-38 is much higher (³80%). 48) Variability in SN-38 pharmacokinetics resulting from glucuronide formation is at least one of the major causes of irinotecan-induced severe toxicity. 16, 49) UGT1A1 polymorphisms: UGT1A1 is the enzyme primarily involved in endogenous bilirubin glucuronidation as well as SN-38 glucuronidation. Decreased bilirubin glucuronidation capacity of UGT1A1 is clearly seen in patients with Gilbert's syndrome, for which the genetic basis has been elucidated. Gilbert's syndrome is most commonly associated with homozygotes of the (TA) 7 allele in the proximal promoter region of UGT1A1 (UGT1A1*28), 50) causing reduced gene expression of UGT1A1. 51) Besides UG-T1A1*28, missense polymorphisms in exon 1 and in the shared exons 2 to 5 have been described. Of particular relevance to East Asian populations, including Japanese, is a mutation in exon 1 (211G>A, G71R), referred to as UGT1A1*6.
52) This mutation reduces catalytic activity by 60% in homozygotes. 53) Several lines of evidence have linked UGT1A1*28 and UGT1A1*6 genotypes to irinotecan-induced toxicity, especially severe neutropenia. [54] [55] [56] [57] Renal failure: Even in cancer patients with severe renal failure, chemotherapeutic agents are given when survival is most likely to be determined by malignancy, not renal dysfunction. Such patients are typically given anticancer drugs that are predominantly metabolized in the liver or eliminated into bile (or both), instead of drugs that are excreted renally. Irinotecan is therefore administered to cancer patients with severe renal dysfunction, because it is extensively subjected to hepatic metabolism and excreted into bile. Urinary excretion of SN-38 accounts for less than 1% of the total administered dose of irinotecan. [58] [59] [60] In a prospective clinical pharmacological study of irinotecan performed by us, the plasma concentration of SN-38, but not irinotecan or SN-38 glucuronide, was significantly higher in patients with severe renal failure who had a CL cr of less than 20 mL/min and were receiving hemodialysis, than in patients without renal failure (terminal elimination rate constant, 0.0084 « 0.0037 vs. 0.081 « 0.034 h ¹1 [mean « standard deviation]).
61)
Mean AUC of SN-38 calculated from 0 to 24 h in the patients with severe renal failure was 1.6-fold greater than that in the patients without renal failure (1.3 « 0.7 vs. 0.83 « 0.55 µM0h).
It should be noted that all patients who had severe renal failure experienced prolonged neutropenia even though they were receiving dialysis. The prolonged neutropenia caused the second course of irinotecan treatment to be delayed. 61) Since SN-38 concentrations have been reported to be still detectable even 500 h after administration of irinotecan in patients with normal renal function, 62) a long period of exposure to relatively high concentrations of SN-38 was postulated to be one of the causes of the prolonged neutropenia in these cancer patients with severe renal failure. Previously, de Jong et al. 63) demonstrated that patients with slower CL cr (35-66 mL/min) had a four-fold higher risk of grade 3 or 4 neutropenia, although the pharmacokinetics of irinotecan and its metabolites did not differ from that in patients with normal kidney. In studies by us 61) and de Jong et al., 64) increased plasma SN-38 concentrations were found only in patients with severe renal failure associated with a CL cr of less than 20 mL/min. These findings suggest that irinotecan is not safe in cancer patients with renal failure, even though this anticancer drug is predominantly metabolized in the liver or excreted into bile (or both).
A study investigating potential mechanism(s) for delayed SN-38 elimination revealed that SN-38 uptake by hepatocytes was significantly inhibited by a mixture of organic anion uremic toxins (3-carboxy-4-methyl-5-propyl-2-furanpropionate [CMPF], indoxyl sulfate, hippuric acid, and indole acetate), when the concentrations of the toxins were clinically relevant. 47) CMPF directly inhibited the uptake of SN-38 by hepatocytes, and most potently inhibited SN-38 uptake mediated by cDNA-expressed OATP1B1 among the uremic toxins tested. In addition, gene expression of OATP1B1 and OATP1B3 in hepatocytes was significantly down-regulated by treatment with the uremic plasma. The inhibition of OATP1B1-mediated SN-38 uptake by uremic toxins and down-regulation of SLCO1B1 gene expression may thus play at least partial roles in the mechanisms causing delayed SN-38 elimination in patients with severe renal dysfunction. Because no pharmacokinetic changes were observed for irinotecan or SN-38 glucuronide, altered CES or UGT1A1 activity appears unlikely, although further studies are required.
Repaglinide is a nonrenally eliminated drug, which is a substrate of OATP transporter. Therefore, the rate of repaglinide metabolism in the liver may be limited by the activity of this uptake transporter. 65, 66) The AUC of repaglinide in patients with severe renal failure was approximately 3-fold higher than that in patients with normal renal function. 67) Zhao et al. 68) simulated the AUC of repaglinide in patients with severe kidney dysfunction, using a physiologically based pharmacokinetic (PBPK) model. Interestingly, approximately 52% reduction in the hepatic uptake of repaglinide by OATP1B1 was needed in a virtual population of patients with severe renal impairment to obtain an AUC value comparable to that observed in vivo, 67) with a repaglinide AUC ratio (renal failure to normal kidney) similar to the observed data. Our results and the findings of Zhao et al. 68) indicate that the elevated pharmacokinetic profile of drugs that are predominantly taken up by OATP1B1 into the liver in patients with renal failure is caused by reduced uptake capacity of OATP1B1. If the reduction in hepatic uptake induced by the direct inhibition of OATP1B1 activity by uremic toxins or by suppression of SLCO1B1 gene expression (or by both) could be quantitatively predicted, PBPK models potentially could be used to calculate appropriate doses for cancer patients with severe renal failure, thereby obtaining AUCs similar to those seen in patients with normal kidneys. However, these findings should be further confirmed with other drugs such as rosuvastatin, an HMG-CoA reductase inhibitor predominantly taken up into liver by OATP1B1, 69) which shows similarly reduced clearance in patients with severe renal failure (CL cr < 30 mL/ min). 70) Confirmation of these findings may lead to the development of a new concept for the establishment of evidence-based treatment strategies for irinotecan as well as other anticancer drugs that are substrates of OATP1B in cancer patients with severe renal dysfunction.
Elderly or obese patients: Pharmacokinetic parameters such as Cmax and AUC of irinotecan, SN-38, and SN-38 glucuronide in patients 65 years or older were comparable to those respective values in younger patients (within 3% of difference), whereas the incidence of delayed diarrhea was higher in older patients, 7) suggesting the higher sensitivity to irinotecan-induced diarrhea of older patients than younger patients. No significant difference has been reported in pharmacokinetic parameters between lean and obese patients.
71)
Polypharmacy: Sasaki et al. 72) retrospectively investigated the associations of adverse drug reactions induced by irinotecan monotherapy or a combination of irinotecan, 5-FU, and Lleucovorin (FOLFIRI) with concomitant medications used to treat comorbidity in Japanese patients with cancer. Multiple concomitant medications were significantly related to severe irinotecanrelated toxicity in patients given monotherapy or FOLFIRI. The incidence of severe irinotecan-related toxic effects increased in parallel to the number of concomitant medications. Thus, polypharmacy must be effectively managed to decrease the risk of adverse drug reactions in patients with cancer who receive irinotecan-based chemotherapy. Methods should be developed to identify the causative drug(s) in polypharmacy that can induce drug-drug interactions.
S-1
S-1 (Taiho Pharmaceutical Co., Ltd., Tokyo, Japan) is an oral anticancer agent that was developed in Japan. This anticancer drug is currently one of the most widely prescribed agents for the treatment of gastric cancer in Japan, serving as a standard option for chemotherapy. [73] [74] [75] Drug design concept of S-1: S-1 is a formulation combining tegafur (FT) with 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate in a molar ratio of 1:0.4:1 (Fig. 3) . 76) FT is a pro-drug of cytotoxic 5-FU. The biotransformation of FT to 5-FU is catalyzed by the liver drug-metabolizing enzyme CYP2A6. 77) The addition of CDHP increases the plasma level of 5-FU, because CDHP prevents degradation of 5-FU by competitively inhibiting dihydropyrimidine dehydrogenase (DPD), 78) which is the ratelimiting enzyme responsible for 5-FU detoxification. 79) Potassium oxonate reduces gastrointestinal toxicity caused by active 5-FU by blocking the orotate phosphoribosyltransferase pathway, which is related to further activation of 5-FU. 80, 81) Pharmacokinetic properties: We have performed a prospective study of S-1 to analyze determinants of the pharmacokinetics of 5-FU, the active component of this preparation. 82) CYP2A6 polymorphisms with deficient (*4A [83] [84] [85] ) or reduced activity (*7 86) ) or reduced protein expression (*9 87, 88) ), and the pharmacokinetics of FT, 5-FU, and CDHP on day 1 were analyzed in 54 Japanese patients with metastatic or recurrent cancer who received S-1. All subjects were classified into three groups according to their CYP2A6 genotype: wild type (*1/*1), one-variant allele (*1/any), or two-variant alleles (combinations other than *1). Multivariate regression analysis revealed that the AUC of 5-FU significantly correlated with the AUC of CDHP, but not with the CYP2A6 genotype. 82) On the other hand, the oral clearance of FT was associated with the CYP2A6 genotype. The oral clearance of FT was significantly lower in patients with two-variant alleles than in patients with the wild type or one-variant allele. The AUC of 5-FU and CDHP negatively correlated with CL cr , since CDHP is predominantly excreted in the urine by glomerular filtration. Thus, the AUC of CDHP affected by renal function is the key determinant of variability in the pharmacokinetics of 5-FU, whereas CYP2A6 variants are responsible for pharmacokinetic variability in FT. 82) Similar results supporting our data were obtained in a phase II study of Korean patients with cancer. 90) Intrinsic metabolic clearance of 5-FU was reported to be 7667 µL/min/g liver, 91) whereas that of FT was calculated to be approximately 21 µL/min/g liver (calculated with 72.4 µL/min/ nmol CYP2A6, 77) 0.0138 nmol CYP2A6/mg microsomal protein, 92) and 21.4 mg microsomal protein/g liver 91) ). Metabolic clearance of 5-FU by DPD is thus approximately 350-fold higher than that of FT by CYP2A6. These results indicate that variability in DPD activity has a greater impact on the pharmacokinetics of 5-FU than does CYP2A6 activity caused by genetic polymorphisms. In this prospective study, the relation between 5-FU pharmacokinetics and S-1-induced toxicity was not evaluated, because of the small number of patients who had toxicity.
Obesity (large body surface area): The package insert of S-1 in Japan recommends an initial fixed dose of 120 mg/day for patients with a BSA of 1. 89) Because the glomerular filtration area is directly related to BSA, 94, 95) the AUC of CDHP decreased as the BSA increased. (3) Therefore, the lower median AUC of 5-FU in patients with a BSA of 1.75 m 2 or greater is attributed to the BSA-dependent decrease in the AUC of CDHP. Japanese cancer patients with a large BSA may therefore not sufficiently benefit from S-1 treatment because of low systemic exposure to active 5-FU after administration of a fixed dose of S-1 (120 mg/day); however, this hypothesis should be confirmed in a prospective setting.
Advanced age: Because of its oral formulation, high effectiveness, and relatively low toxicity, S-1 may be particularly suited for the treatment of cancer in elderly patients. 96) However, clinical trials of S-1 have only involved participation of patients 75 years or younger. 89, 97) Given that the pharmacokinetics of FT, 5-FU, and CDHP are potentially affected by aging, current dosage recommendations for S-1 might not produce adequate serum levels of the active metabolite 5-FU in elderly patients. Therefore, a retrospective subset analysis comparing the pharmacokinetics of FT, 5-FU, and CDHP between patients 75 years or older and those younger than 75 years was performed to assess the effects of aging on the pharmacokinetics of the components of S-1.
98) The median AUC of the active metabolite 5-FU did not significantly differ between 10 patients 75 years or older and 53 patients younger than 75 years. Interestingly, the median oral clearance of FT mediated by CYP2A6 in patients 75 years or older was significantly lower than that in patients younger than 75 years. An age-related decline in CYP2A6 activity is supported by the previous observation that decreased coumarin clearance in the elderly is associated with reduced CYP2A6 activity. 33) Furthermore, the median AUC of CDHP was significantly higher in patients 75 years or older than in those younger than 75 years, probably reflecting reduced renal function in the elderly, since CDHP is excreted in the urine by glomerular filtration. 89) Indeed, the median CL cr in patients 75 years or older in the subset analysis was significantly lower than that in younger patients, 98) which is consistent with previous observations that renal function often decreases with advancing age.
99) The opposing effects of aging on the oral clearance of FT and the AUC of CDHP may offset each other, leading to unchanged systemic exposure to 5-FU. The pharmacokinetics as well as toxicity of S-1 in elderly patients should be evaluated in prospective studies.
Possibility of therapeutic drug monitoring for S-1: Clinically, the main prerequisites of therapeutic drug monitoring (TDM) are a narrow therapeutic index and high inter-individual variability, a well-defined concentration-effect relationship, and the availability of reliable and clinically feasible assays. In oncology, methotrexate remains the only anticancer drug for which TDM is routinely performed in clinical practice; even then, drug levels are used to ensure safety rather than to optimize anticancer efficacy. 100) There are many barriers to the acceptance of TDM in oncologic practice in the pretargeted therapy era (cytotoxic anticancer agents), such as the lack of established therapeutic ranges and concentration-effect relationships, the frequent use of multidrug combinations with overlapping therapeutic and toxic effects, and the use of prodrugs or drugs with active metabolites. Perhaps most importantly, because these traditional drugs have a relatively short elimination half-life and are given by intermittent intravenous infusions, multiple blood samples are needed to adequately define systemic exposure, which renders TDM impractical for routine use in the clinical care of patients with cancer. 101) Because concentration-effect relationships and target therapeutic ranges have been established for intravenous infusion of 5-FU, TDM has been shown to improve clinical outcomes in patients with metastatic colorectal cancer who receive high-dose leucovorin and 5-FU.
102) S-1 is an oral formulation given daily to patients, although FT contained in this formulation is a prodrug. A linear relation between a single dose of S-1 and the AUC of 5-FU was demonstrated in both Japanese 103) and European 104) patients with cancer. 5-FU exposure was shown to be associated with S-1-induced toxic effects in Western patients, [104] [105] [106] but not in Korean patients. 90) If the effective therapeutic range and concentrationeffect relationships of 5-FU can be determined even in 'real world' patients who receive S-1, TDM might be useful for individual dose adjustment. However, much effort would be required to define effective therapeutic ranges and concentration-response relationships in such patients.
Conclusions
The number of medically unfit patients with conditions such as obesity or advanced age continues to increase throughout the world. The increased incidence of malignancies in patients with chronic renal insufficiency is now well established. [107] [108] [109] The situation in Japan is no exception. Evidence-based chemotherapy will be increasingly needed for cancer management in these unfit patients in the 'real world.' Although a wide range of clinical pharmacological studies have been performed in Western countries, adequate evidence seems to be lacking, and most reports recommend further clinical pharmacological studies to more clearly define the pharmacokinetics and pharmacodynamics of cancer therapies in such patients. On the other hand, the number of clinical pharmacological studies performed in Japan is much smaller than that performed in Western countries. Thus, we will have to perform multicenter pharmacokinetic and pharmacodynamic studies of an adequate sample size, including thorough evaluations of physiologic factors in unfit patients, to better understand the factors affecting treatment tolerance and efficacy. Although considerable effort will be required, these approaches will provide a basis for establishing appropriate dose regimens of chemotherapy and other interventions for unfit patients in the 'real world,' thereby maximizing efficacy and minimizing toxicity.
